In addition, ICC has advocated subclassifying MDS/AML into (1) MDS/AML with myelodysplastic-related gene mutations, (2) MDS/AML-NOS, and (3) MDS/AML with mutated TP53. This evidence concerns the gene TP53 and acute myeloid leukemia.